Hướng dẫn chẩn đoán và điều trị bệnh tăng cholesterol máu gia đình tại Việt Nam
Tóm tắt
Bệnh tăng cholesterol máu gia đình (bệnh FH) là bệnh rối loạn chuyển hóa lipid máu di truyền, đặc trưng bởi LDL-C máu tăng cao và bệnh mạch vành sớm. Tại Việt Nam, hiểu biết về bệnh lý này còn hạn chế. Do đó, Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai đưa ra hướng dẫn chẩn đoán và điều trị bệnh FH. Đây là hướng dẫn đầu tiên về bệnh FH tại Việt Nam. Hướng dẫn này nhằm cải thiện chẩn đoán và điều trị bệnh FH tại Việt Nam.
Từ khóa: Tăng cholesterol máu gia đình, chẩn đoán, điều trị.
Tài liệu tham khảo
1. Akioyamen, L.E., et al., Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open, 2017. 7(9): p. e016461.
2. Vallejo-Vaz, A.J., et al., Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018. 277: p. 234-255.
3. Watts, G.F., et al., Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond. J Atheroscler Thromb, 2016. 23(8): p. 891-900.
4. Pang, J., et al., An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study". BMJ Open, 2017. 7(10): p. e017817.
5. Pang, J., et al., Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". J Clin Lipidol, 2019. 13(2): p. 287-300.
6. Truong, T.H., et al., Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis, 2018. 277: p. 392-398.
7. Harada-Shiba, M., et al., Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb, 2018. 25(8): p. 751-770.
8. Soutar, A.K. and R.P. Naoumova, Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007. 4(4): p. 214-25.
9. Kim Ngọc Thanh, Trần Trung Thành, Trần Đức Huy, Lê Hồng An, Trương Thanh Hương, Nghiên cứu bước đầu về tình trạng bệnh tăng cholesterol máu có tính gia đình ở các trường hợp mắc bệnh mạch vành sớm. Journal of Vietnamese Cardiology. Journal of Vietnamese Cardiology, 2018. 81: p. 33-37.
10. Starr, B., et al., Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med, 2008. 46(6): p. 791-803.
11. Cuchel, M., et al., Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014. 35(32): p. 2146-57.
12. Wiegman, A., et al., Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European heart journal, 2015. 36(36): p. 2425-2437.
13. Li, S., et al., Familial hypercholesterolemia in very young myocardial infarction. Scientific Reports, 2018. 8(1): p. 8861.
14. Groselj, U., et al., Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis, 2018. 277: p. 383-391.
15. Klancar, G., et al., Universal Screening for Familial Hypercholesterolemia in Children. J Am Coll Cardiol, 2015. 66(11): p. 1250-1257.
16. Lazaro, P., et al., Cost-effectiveness of a cascade screening program for the early detection of familia
hypercholesterolemia. J Clin Lipidol, 2017. 11(1): p. 260-271.
17. Leren, T.P., et al., Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet, 2008. 11(1): p. 26-35.
18. Mach, F., et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 2019.
19. Brunham, L.R., et al., Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol, 2018. 34(12): p. 1553-1563.
20. Gagne, C., D. Gaudet, and E. Bruckert, Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002. 105(21): p. 2469-75.
21. Menzin, J., et al., Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. J Manag Care Spec Pharm, 2017. 23(12): p. 1270-1276.
22. Stein, E.A., et al., Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet, 2012. 380(9836): p. 29-36.
23. Gouni-Berthold, I., et al., Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. 2016. 82(6): p. 1412-1443.
24. Blaha, M., et al., Pregnancy in homozygous familial hypercholesterolemia-Importance of LDL-apheresis. Atheroscler Suppl, 2015. 18: p. 134-9.
25. Ogura, M., et al., Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis, 2016. 254: p. 179-183.
26. Thompson, G.R., et al., Assessment of long-term plasma exchange for familial hypercholesterolaemia. British Heart Journal, 1980. 43(6): p. 680-688.
27. Martinez, M., et al., Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia. Am J Cardiol, 2016. 118(4): p. 504-10.
28. Kawasuji, M., et al., Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. J Thorac Cardiovasc Surg, 2000. 119(5): p. 1008-13; discussion 1013-4.
29. Nazif, T.M., et al., Percutaneous Coronary Intervention With Bioresorbable Scaffolds in a Young Child. JAMA Cardiol, 2017. 2(4): p. 430-434.
30. Ravat, H., S. Garekar, and V. Changela, Left Main coronary angioplasty of a 9-year-old child with bioresorbable vascular scaffold [corrected]. Catheter Cardiovasc Interv, 2017. 89(5): p. 867-871.
